COMMENTARY

Have AGs Finally Become a Good Option to Counter Generics?

January 19, 2015
With generics rapidly replacing off-patent branded drugs after the introduction of generic-use incentives in April 2014, we can expect to see more and more original drug makers launch authorized generics (AGs). ASKA Pharmaceutical rolled out an AG of Takeda Pharmaceutical’s…

To read the full story

COMMENTARY

By Philip Carrigan

As the year 2022 draws to a close, what are managers thinking at the world’s leading pharmaceutical companies and medical device companies? We surveyed 86 managers at these companies to find out what’s on their minds.For many managers, a common…

By Yoshinori Sagehashi

Debates on the planned FY2023 off-year drug price revision are now entering the final stretch. Healthcare providers and payers have made their conflicting positions clear on the scope of products to be covered by the re-pricing, while the pharma industry…

A Japanese reimbursement policy panel on November 16 saw a continued scuffle between members representing healthcare providers and payers over…

Deloitte Tohmatsu Consulting proposed three drug pricing schemes designed to trigger the consolidation of generic makers on October 27, offering…

Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…